GlassScriptPhysician profile
Ritesh Kohli
NPI 1497061972
$17,665.19
in general payments reported to CMS, 2019-2025
39 companies · $4,302 in 2025
The $4,302 reported for 2025 was more than what 84% of Rheumatology providers received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,906 · 2020: $1,481 · 2021: $1,788 · 2022: $1,772 · 2023: $3,178 · 2024: $3,238 · 2025: $4,302.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $10K · Education: $373.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $10,344.33 |
| Education | $373.31 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,532.43 | 2019-2025 | |
| Janssen Biotech, INC. | $2,242.96 | 2020-2025 | Tremfya, Simponi Aria |
| Ucb, INC. | $1,961.14 | 2019-2025 | Bimzelx, Cimzia |
| Novartis Pharmaceuticals Corporation | $1,321.31 | 2020-2025 | |
| Ani Pharmaceuticals, INC. | $946.80 | 2023-2025 | Purified Cortrophin Gel, Sovuna |
| Glaxosmithkline, LLC. | $812.29 | 2021-2025 | Benlysta, Nucala |
| Amgen INC. | $772.91 | 2020-2025 | Evenity, Tavneos, Otezla |
| Astrazeneca Pharmaceuticals LP | $672.79 | 2021-2025 | Saphnelo |
| Pfizer INC. | $630.20 | 2019-2025 | |
| Lilly USA, LLC | $627.64 | 2019-2024 | Taltz |
| Mallinckrodt Hospital Products INC. | $625.29 | 2021-2025 | Acthar |
| Horizon Therapeutics Plc | $564.04 | 2019-2023 | Krystexxa |
| E.R. Squibb & Sons, L.L.C. | $537.70 | 2019-2025 | Orencia |
| Genentech USA, INC. | $443.30 | 2019-2025 | Actemra, Gazyva |
| Radius Health, INC. | $420.22 | 2020-2025 | Tymlos |
Show all 39 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aurinia Pharma U.S., INC. | $296.31 | 2022-2025 | Lupkynis |
| Sanofi-Aventis U.S. LLC | $201.09 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $163.01 | 2019-2023 | |
| Organon LLC | $99.02 | 2023-2025 | Renflexis, Hadlima |
| Medexus Pharma, INC. | $91.16 | 2019-2021 | |
| Fidia Pharma USA INC. | $82.06 | 2021-2025 | Hymovis, Triluron |
| Arcutis Biotherapeutics, INC. | $81.92 | 2023 | |
| Genzyme Corporation | $70.88 | 2019-2022 | |
| Sandoz INC. | $67.51 | 2023-2025 | Hyrimoz |
| Antares Pharma, INC. | $65.69 | 2020-2021 | |
| Celgene Corporation | $36.15 | 2019 | |
| Actelion Pharmaceuticals US, INC. | $35.51 | 2025 | Uptravi, Opsumit |
| Depuy Synthes Sales INC. | $34.61 | 2020 | |
| Fresenius Kabi USA, LLC | $27.92 | 2025 | |
| Mallinckrodt Enterprises LLC | $27.11 | 2019 | |
| Janssen Pharmaceuticals, INC | $26.31 | 2025 | Tremfya |
| Invivyd INC | $24.24 | 2025 | Pemgarda |
| Almatica Pharma LLC | $20.55 | 2025 | Teriparatide |
| Abbott Laboratories | $19.49 | 2024 | Proclaim |
| Sobi, INC | $19.22 | 2025 | |
| Octapharma USA, INC. | $18.78 | 2023 | Octagam Immune Globulin (Human) |
| Mylan Institutional INC. | $17.72 | 2023 | |
| Ferring Pharmaceuticals INC. | $16.29 | 2019 | |
| Merck Sharp & Dohme LLC | $11.62 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ritesh Kohli listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.